Genmab — August 2020
-
Shares of Genmab A/S (NASDAQ:GMAB) reached a new 52-week high on Friday after HC Wainwright raised their price target on the stock from $40.00 to $41.00. HC Wainwright currently has a buy rating on the stock. Genmab A/S traded as high as $38.31 and last traded at $38.31, with a volume of 9217 shares traded. The stock had previously closed at $37.35.
-
-
GMAB 15:11 08/21/20 Genmab to hold a conference call CEO van de Winkel holds a company update conference call on August 26 -
https://thefly.com/landingPageNews.php?id=3150049&headline=GMAB--Genmab-to-hold-a-conference-call- - I wonder who organised that
-
The very important conference call on 26 August, Danish time 4.30 pm is announced here. Organizer and analysts are from the famous Genmab chat. https://ir.genmab.com/events-and-presentations#content
-
-
Questions are very welcome as soon as possible.
-
Fra DnB: Target price raised to DKK2,455 (2,450); HOLD reiterated. Following the approval of Kesimpta, we have lifted our probability of success to 100% (previously 95%), adding DKK5 to our target price. However, we believe this is well reflected in the stock price.
-
God morrgen.
-
Hvornår går Kesimpta af patent? Azerras patent udløber så vidt jeg finde oplysninger om i 2023. Da Ofa i Kesimpta er anderledes (sc) ligger udløb længere ude i fremtiden, men jeg kan ikke finde slutåret?
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind